Ting Bao, M.D., from the University of Maryland Greenebaum Cancer Center in Baltimore, and colleagues randomized postmenopausal women with stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms to receive eight weekly RA (23 patients) or SA (24 patients) sessions.

"Both RA and SA were associated with improvement in patient-reported outcomes among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms," the authors conclude.